Lifotronic Technology Released 2022 Annual Report

On April 28, Lifotronic Technology Co., Ltd. released its 2022 annual report. 

During the reporting period, the total operating revenue was CNY 983 million, an increase of 26.34% year-on-year; the net profit attributable to the mother company was CNY 251 million, an increase of 32.12% over the same period of the previous year; the net profit after deduction of non-net profit was CNY 233 million, an increase of 42.98% over the same period of the previous year; the operating cash flow was CNY 272 million, an increase of 49.24% year-on-year, and the ratio of sales receivables to annual sales revenue at the end of the year was 9.68%, the company's operating and financial position is good.

Among them, the in vitro diagnostic category achieved revenue of CNY 749 million, up 26.35% year-on-year; the therapy and rehabilitation category achieved revenue of CNY 227 million, up 26.07% year-on-year. 

The revenue from sales of in vitro diagnostic products is the main component of the company's revenue, accounting for 76%. During the reporting period, the core clinical medical products in the treatment and rehabilitation product line, such as air wave, sputum removal machine and high-flow oxygen therapy instrument, continued to maintain good performance growth, while the skin medical beauty series products were gradually promoted in volume, gaining industry praise and performance growth of new business segments. 

The competitiveness of in vitro diagnostic products in the domestic and international markets has been further improved, and clinical applications have continued to increase in volume, especially the two series of products of luminescence and glycation have driven the related performance growth.

Reviewing the past performance, the operating revenue from 2016 to 2022 grew from CNY 175 million to CNY 983 million, achieving a compound growth rate of 33.39%; the net profit attributable to the mother grew from CNY 33,367,100 (excluding share-based payment of CNY 23,487,900) to CNY 251 million, achieving a compound growth rate of 40.02%; the operating cash flow grew from CNY 27,999,800 to CNY 272 million, with a compound growth rate of 46.05%.